Research map: Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. Utility of Circulating Tumor DNA as a Monitoring Tool for Marker-Negative Germ Cell Tumors and Somatic Type Malignancies · 2026 · Related
  3. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma · Robert John Motzer · 2015 · 5978 citations · Cited by this paper
  4. The Utility of the Comprehensive Complication Index in Demonstrating the Complication Burden and Predicting Length of Stay in Robot-Assisted Radical Prostatectomy · 2026 · Related
  5. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma · Robert John Motzer · 2018 · 4768 citations · Cited by this paper
  6. Exploration of the Challenges in the Management of Prostate Cancer in East Africa · 2025 · Related
  7. Comprehensive molecular characterization of clear cell renal cell carcinoma · Chad J. Creighton · 2013 · 3607 citations · Cited by this paper
  8. Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study · 2026 · Related
  9. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma · Brian I. Rini · 2019 · 3495 citations · Cited by this paper
  10. Immunophenotyping and Molecular Patterns of Prostate Cancer in East Africa: Diagnostic and Prognostic Implications—A Systematic Review · 2026 · Related
  11. Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway · William G. Kaelin · 2008 · 3313 citations · Cited by this paper
  12. Impact of Age on Outcomes in Metastatic Non–Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT) · 2026 · Related
  13. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma · Robert John Motzer · 2019 · 2593 citations · Cited by this paper
  14. Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis · 2026 · Related
  15. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study · Daniel Y.C. Heng · 2009 · 2161 citations · Cited by this paper
  16. A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer · 2025 · Related
  17. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma · Robert John Motzer · 2021 · 1811 citations · Cited by this paper
  18. Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules · 2025 · Related
  19. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma · Toni K. Choueiri · 2021 · 1801 citations · Cited by this paper
  20. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma · Diana Miao · 2018 · 1326 citations · Cited by this paper
  21. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma · Toni K. Choueiri · 2015 · 1248 citations · Cited by this paper
  22. Targeting renal cell carcinoma with a HIF-2 antagonist · Wenfang Chen · 2016 · 745 citations · Cited by this paper
  23. Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease · Eric Jonasch · 2021 · 700 citations · Cited by this paper
  24. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal · Samra Turajlic · 2018 · 692 citations · Cited by this paper
  25. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation · Payal Kapur · 2013 · 473 citations · Cited by this paper
  26. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models · Hyejin Cho · 2016 · 470 citations · Cited by this paper
  27. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma · Kevin Dale Courtney · 2017 · 399 citations · Cited by this paper
  28. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis · Toni K. Choueiri · 2021 · 308 citations · Cited by this paper
  29. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study · Brian I. Rini · 2019 · 266 citations · Cited by this paper
  30. 3-[(1 S ,2 S ,3 R )-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma · Rui Xu · 2019 · 218 citations · Cited by this paper
  31. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma · Toni K. Choueiri · 2024 · 181 citations · Cited by this paper
  32. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study · Martin Henner Voss · 2018 · 147 citations · Cited by this paper
  33. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia · Rodrigo Almeida Toledo · 2022 · 95 citations · Cited by this paper
  34. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC · Jenny Jaeeun Ko · 2014 · 72 citations · Cited by this paper
  35. Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study · Toni K. Choueiri · 2025 · 30 citations · Cited by this paper
  36. Belzutifan for HIF2A-Related Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data · Hussam R Alkaissi · 2025 · 12 citations · Cited by this paper
  37. A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: insights from the FDA adverse event reporting system database · Ye Yang · 2025 · 7 citations · Cited by this paper
  38. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma · Emily Wang · 2024 · 4 citations · Cited by this paper
  39. Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group · Concetta Calabrò · 2026 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)